Tempus Wealth Planning LLC Purchases 191 Shares of Laboratory Co. of America Holdings (NYSE:LH)

Tempus Wealth Planning LLC boosted its stake in Laboratory Co. of America Holdings (NYSE:LH) by 9.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,180 shares of the medical research company’s stock after acquiring an additional 191 shares during the period. Tempus Wealth Planning LLC’s holdings in Laboratory Co. of America were worth $500,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in LH. Sanctuary Advisors LLC bought a new stake in Laboratory Co. of America in the second quarter valued at $2,268,000. AMF Tjanstepension AB boosted its holdings in shares of Laboratory Co. of America by 37.0% during the 3rd quarter. AMF Tjanstepension AB now owns 86,026 shares of the medical research company’s stock valued at $19,232,000 after buying an additional 23,221 shares in the last quarter. Park Avenue Securities LLC bought a new stake in shares of Laboratory Co. of America during the 3rd quarter valued at $1,189,000. Czech National Bank boosted its holdings in shares of Laboratory Co. of America by 6.5% during the 3rd quarter. Czech National Bank now owns 17,104 shares of the medical research company’s stock valued at $3,822,000 after buying an additional 1,040 shares in the last quarter. Finally, GAMMA Investing LLC boosted its holdings in shares of Laboratory Co. of America by 43.3% during the 3rd quarter. GAMMA Investing LLC now owns 1,601 shares of the medical research company’s stock valued at $358,000 after buying an additional 484 shares in the last quarter. Institutional investors own 95.94% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. Bank of America boosted their target price on shares of Laboratory Co. of America from $262.00 to $271.00 and gave the company a “buy” rating in a report on Friday, December 13th. HSBC upgraded shares of Laboratory Co. of America from a “hold” rating to a “buy” rating in a report on Wednesday, October 30th. Evercore ISI raised Laboratory Co. of America from an “in-line” rating to an “outperform” rating and lifted their price target for the stock from $260.00 to $265.00 in a research report on Tuesday, January 7th. Piper Sandler lifted their price target on Laboratory Co. of America from $235.00 to $240.00 and gave the stock a “neutral” rating in a research report on Monday, October 28th. Finally, Morgan Stanley lifted their price target on Laboratory Co. of America from $260.00 to $270.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 17th. Four investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $263.46.

Insider Buying and Selling at Laboratory Co. of America

In other Laboratory Co. of America news, EVP Glenn A. Eisenberg sold 11,711 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $240.43, for a total value of $2,815,675.73. Following the completion of the transaction, the executive vice president now directly owns 31,289 shares in the company, valued at $7,522,814.27. This represents a 27.23 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Kerrii B. Anderson sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $235.00, for a total value of $235,000.00. Following the sale, the director now directly owns 12,722 shares in the company, valued at $2,989,670. This trade represents a 7.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 24,572 shares of company stock worth $5,915,209 in the last three months. 0.85% of the stock is currently owned by company insiders.

Laboratory Co. of America Trading Down 0.5 %

Laboratory Co. of America stock opened at $246.70 on Wednesday. The business has a 50-day simple moving average of $236.14 and a two-hundred day simple moving average of $228.95. The company has a market cap of $20.63 billion, a P/E ratio of 47.72, a P/E/G ratio of 1.86 and a beta of 1.07. Laboratory Co. of America Holdings has a 52-week low of $191.97 and a 52-week high of $258.59. The company has a quick ratio of 1.30, a current ratio of 1.44 and a debt-to-equity ratio of 0.66.

Laboratory Co. of America Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, March 12th. Shareholders of record on Thursday, February 27th will be paid a dividend of $0.72 per share. The ex-dividend date is Thursday, February 27th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.17%. Laboratory Co. of America’s dividend payout ratio is currently 55.71%.

Laboratory Co. of America Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.